Cytosolic-free oligosaccharides are predominantly generated by the degradation of dolichol-linked oligosaccharides in mammalian cells 
Introduction
In the lumen of the endoplasmic reticulum (ER) of most eukaryotes, the oligosaccharyltransferase (OST) catalyzes the transfer of a tetradecaoligosaccharide (Glc 3 Man 9 GlcNAc 2 ) from the corresponding dolichol-linked precursor (dolichol-linked oligosaccharide; DLOs) to a specific asparagine residue within the consensus sequence (N-X-S/T, X ≠ P) of a nascent polypeptide (Figure 1 ) (Kelleher and Gilmore 2006; Aebi 2013) . As a by-product of N-glycosylation, relatively large amounts of a protein-unbound form of high-mannose-type glycans (free oligosaccharides; fOSs), which contain a N,N′-diacetylchitobiose core (Gn2-type) at the reducing end, are present in the cytosol of mammalian cells (Anumula and Spiro 1983) . It was initially reported that such fOSs are produced in the ER lumen by the hydrolysis of DLOs, presumably by OST [ Figure 1 , step (i)] (Anumula and Spiro 1983) and are then rapidly transported to the cytosol via a putative fOS transporter (Moore et al. 1995) . However, the identification and characterization of a cytosolic peptide:N-glycanase (PNGase) (Suzuki et al. 1993 (Suzuki et al. , 2003 and a study of its biological function in which PNGase deglycosylates misfolded glycoproteins during ER-associated degradation (ERAD) [Figure 1, step (ii) ] (Wiertz et al. 1996; Yu et al. 1997; Suzuki et al. 2000; Kim et al. 2006; He et al. 2015; Huang et al. 2015) indicated that fOSs are produced via an alternative pathway, i.e. from glycoproteins in the cytosol.
The resulting fOSs are catabolized in the cytosol by the removal of the innermost GlcNAc residue by a cytosolic endo-β-N-acetylglucosaminidase (ENGase) (Suzuki et al. 2002; Kato et al. 2007) , followed by mannose trimming by a class II α-mannosidase (Man2C1) ) to produce a Gn1-type, homogeneous glycan structure, i.e. Man 5 GlcNAc 1 . This process, termed nonlysosomal glycan degradation (Suzuki and Harada 2014) , plays a crucial role in the delivery of fOSs to lysosomes where the molecules are degraded to monosaccharides (Saint-Pol et al. 1997) . Although the catabolic pathway for fOSs has been well characterized, much less is known regarding the relative contribution of the OST-mediated degradation of DLOs and the PNGase-mediated deglycosylation of glycoproteins to fOSs in mammalian cells.
In Saccharomyces cerevisiae, the deletion of PNG1, the yeast ortholog of PNGase (Suzuki et al. 2000) , results in a dramatic reduction in the production of fOSs (Hirayama et al. 2010; Harada, Buser, et al. 2013) , clearly indicating that a large fraction of the cytosolic fOSs arises via a Png1-dependent process in S. cerevisiae. To investigate fOS formation in mammalian cells, we analyzed the glycan structures and the amounts of fOSs produced in mouse embryonic fibroblasts (MEFs) which do not produce the deglycosylating enzymes that are involved in glycoprotein ERAD and compared the results with corresponding results for wild-type MEFs. The findings indicate that the knockout of the cytosolic deglycosylating enzymes does not significantly alter the amounts of fOSs that are produced, and that the cytosolic fOSs are predominantly produced by the hydrolysis of DLOs, i.e. a reaction presumably mediated by OST.
Results

A large fraction of fOSs is formed independent of the action of Ngly1 and ENGase
We previously reported that, in MEFs, the knockout of Ngly1, the mouse ortholog of the gene encoding the cytoplasmic PNGase (Suzuki Fig. 1 . Proposed model for the generation and non-lysosomal degradation of fOSs in mammalian cells (Ninagawa et al. 2014; Suzuki and Harada 2014) . During N-glycosylation, fOSs can be produced by either the degradation of DLOs (i) or the deglycosylation of misfolded glycoproteins by PNGase (ii). In the ER lumen, glycan trimming of the Glc 3 Man 9 GlcNAc 2 oligosaccharide by ER glycosidases (GI/II and presumably ERManI or EDEM2) accelerates the ER-to-cytosol transport of luminal fOSs via an unidentified fOS transporter (Moore et al. 1995) . In the cytosol, ENGase and Man2C1 process fOSs derived from both misfolded glycoproteins and DLOs, generating Man 5 GlcNAc 1 oligosaccharide.
et al. 2003) , causes the dysregulation of ERAD in a mutant form of ricin toxin A chain (RTAΔ) (Huang et al. 2015) , indicating that the Ngly1-mediated deglycosylation of misfolded glycoproteins is important in ERAD. Moreover, our findings indicated that, in the absence of Ngly1, ENGase deglycosylates RTAΔ to generate an aggregationprone, N-GlcNAc-modified protein (Huang et al. 2015) , thus demonstrating that ENGase has the ability to function as a deglycosylating enzyme. In the present study, MEF cells in which both the Ngly1 and Engase genes (Ngly1 −/− Engase −/− MEFs) had been deleted were used to investigate the contribution of glycoprotein ERAD to fOS production. fOSs extracted from whole cells were labeled with 2-aminopyridine (PA) and the resulting derivatives were analyzed by size-fractionation high-pressure liquid chromatography (HPLC). The results showed that wild-type and Ngly1 −/− Engase −/− MEFs produced fOSs with different HPLC profiles, particularly in the range of 5-11 glucose units (GU) (Figure 2A ). To determine the structures and quantities of fOSs in wild-type and Ngly1 −/− Engase −/− MEFs, labeled fOSs were initially subjected to size-fractionation HPLC (Hirayama et al. 2010 ) and the resulting fractions were further analyzed by dual-gradient, reversed-phase HPLC (Suzuki et al. 2008 ) (Figure 2B and C; Supplementary data, Tables S1 and S2 for glycan structures and their abbreviations; see also Supplementary data, Tables S3 for the detailed quantification of fOSs). In the case of wild-type MEFs, various Gn1-( Figure 2C , top panel) and Gn2-types ( Figure 2C , bottom panel) of high-mannose-type fOSs were detected. Among the fOSs detected in wild-type MEFs, the M5B′ isoform (Man 5 GlcNAc 1 ) was the most abundant ( Figure 2C , top panel). In contrast, the M5B′ isoform was barely detected in Ngly1 −/− Engase −/− MEFs, while larger Gn2-type fOSs, such as Man 8-9 GlcNAc 2 , accumulated ( Figure 2C , bottom panel). Although dramatic structural alterations in the fOSs were observed in Ngly1 −/− Engase −/− MEFs, the total amount of fOSs produced was comparable with that of wild-type MEFs ( Figure 2D ). The accumulation of Gn2-type fOSs was also observed in Engase −/− single-knockout MEFs, but not in Figure 2E ). The HPLC profiles between the Ngly1 −/− Engase −/− MEFs and Engase −/− , but not Ngly1 −/− , MEFs were very similar, because the former two cells predominantly generate Gn2-type fOSs, while the latter generates Gn1-type fOSs that are analogous to those produced by wild-type MEF cells (Figure 1) , because of the presence of ENGase. Based on these results, we concluded that the generation of a large fraction of the fOSs was independent of the cytosolic deglycosylation of misfolded glycoproteins by Ngly1 and ENGase and that the structures of the fOSs are markedly altered by the presence of ENGase.
Gn2-type fOSs accumulate in the cytosol of Ngly1
Although our analyses of MEFs revealed that fOSs were generated in an Ngly1-and ENGase-independent manner in mammalian cells, the underlying mechanism responsible for this remained unclear. To clarify this issue, the subcellular localization of fOSs in Ngly1 −/− Engase −/− MEFs was investigated using cells that had been treated with various concentrations of digitonin to induce membrane permeabilization, allowing for the separation of soluble and organelle fractions. At a digitonin concentration of 0.025%, the cytosolic marker lactate dehydrogenase (LDH) was completely released into the soluble fraction ( Figure 3A) , whereas a lysosomal luminal protein (β-hexosaminidase; β-HexNAcase, Figure 3A) , as well as an ER luminal protein ( protein disulfide isomerase; PDI, Figure 3B ), remained associated with the organelle fraction. This result shows that the plasma membrane, and not the ER or lysosomal membrane, was permeabilized by the 0.025% digitonin treatment.
Having established the specific conditions needed to render the plasma membrane permeable, the structures and quantities of fOSs in the cytosolic and organelle fractions were analyzed by dualgradient, reversed-phase HPLC. Structural analyses of wild-type ( Figure 3C ) and Ngly1 −/− Engase −/− ( Figure 3D ) MEFs revealed that, in the two cell lines, fOSs in the organelle fraction ( Figure 3C and D, white bars) were mainly comprised of both Gn1-and Gn2-types, with oligosaccharides containing less than three mannose residues (see also Supplementary data, Tables S4 and S5 ). The truncated glycan structures and organelle association of these fOSs suggested that they were most likely derived from the lysosomal compartment. In the cytosol of wild-type MEFs, Gn1-type of fOSs including the M4D′, M5B′ and G1M5B′ isoforms constitute the major fraction (87%) of the fOSs ( Figure 3C , black bars). In contrast, most of the cytosolic fOSs in Ngly1 −/− Engase −/− MEFs were found to be Gn2-type of fOSs and the majority (84%) consisted of Man [8] [9] GlcNAc 2 ( Figure 3D , black bars). Since the MEFs lacked cytoplasmic Ngly1, which generates Gn2-type fOSs from misfolded glycoproteins, it is not likely that the Man 8-9 GlcNAc 2 oligosaccharides originated from glycoprotein sources.
Cytosolic fOSs originate from the ER lumen
The formation of Ngly1-independent Gn2-type fOSs was speculated to be due to DLO degradation. Metabolic labeling experiments using 2-[ 3 H]-mannose have shown that the degradation of Glc 3 Man 9-GlcNAc 2 -PP-Dol occurs in the ER lumen, resulting in the release of Glc 3 Man 9 GlcNAc 2 (Gao et al. 2005) , which is subsequently trimmed to Man 8-9 GlcNAc 2 by ER glucosidases I/II (GI/II) and class I mannosidase(s) (Moore et al. 1995) and then transported to the cytosol by a currently unidentified fOS-transporter on the ER membrane (Moore et al. 1995; Haga et al. 2009 ). Here, we attempted to detect the formation of Glc 3 Man 9 GlcNAc 2 in Ngly1 −/− Engase −/− MEFs under nonradiolabeling conditions by treating the cells with castanospermine (CST) and kifunensine (KIF) to inhibit the action of GI/II and class I α-mannosidases, respectively. The rationale behind this experiment is that, since it has been suggested that glucosylated fOSs are relatively poor substrates for the oligosaccharide transport reaction from the ER to the cytosol (Moore et al. 1995; Haga et al. 2009 ), we examined the issue of whether the accumulation of luminal Glc 3 Man 9 GlcNAc 2 could be observed in the organelle fraction as a result of this treatment.
In non-treated cells, Glc 3 Man 9 GlcNAc 2 was undetectable ( Figure 4A ). In contrast, the CST treatment of MEFs resulted in the accumulation of Glc 3 Man 9 GlcNAc 2 , which was detected at even higher levels in MEFs that had been co-treated with CST and KIF. Upon the inhibitor treatment, triglucosylated fOSs were the predominant species that accumulated when compared with mono-and diglucosylated fOSs (data not shown), indicating that CST efficiently inhibited the action of GI. It was also found that these inhibitors had only minor effects on the metabolism of the non-glucosylated fOS pools (data not shown), suggesting that the inhibitors specifically inhibited the catabolism of glucosylated fOSs. Furthermore, the digitoninpermeabilization experiments revealed that, in the presence of CST and KIF, ∼34% of the Glc 3 Man 9 GlcNAc 2 was associated with the organelle fraction ( Figure 4B ). These collective observations are consistent with the earlier findings showing that Glc 3 Man 9 GlcNAc 2 is generated in the ER lumen (Hanover and Lennarz 1982; Moore et al. 1995) . followed by dual-gradient, reversed-phase HPLC (Suzuki et al. 2008) , and by comparisons of the elution positions with the standard glycans. For detailed glycan structures, see Supplementary data, Tables S1 and S2. *, not detected.
Glc 3 Man 9 GlcNAc 2 is generated by the degradation of Glc 3 Man 9 GlcNAc 2 -PP-Dol
To determine whether luminal Glc 3 Man 9 GlcNAc 2 is generated by the degradation of Glc 3 Man 9 GlcNAc 2 -PP-Dol, we reconstituted DLO degradation using the organelle fraction of digitonin-permeabilized Ngly1 −/− Engase −/− MEFs, which contains endogenous Glc 3 Man 9-GlcNAc 2 -PP-Dol and Man 9 GlcNAc 2 -PP-Dol as the major DLOs ( Figure 5A , 0 min). The reaction was performed in the presence of CST and KIF to prevent glycan trimming. After a 20 min incubation, the level of Man 9 GlcNAc 2 -PP-Dol reached negligible, while Glc 3-Man 9 GlcNAc 2 -PP-Dol was gradually reduced over the 2 h incubation period ( Figure 5A ). The rapid reduction in Man 9 GlcNAc 2 -PP-Dol levels was not likely due to demannosylation by α-mannosidases, because DLO intermediates smaller than Man 9 GlcNAc 2 -PP-Dol were undetectable during the incubation period (data not shown). This observation indicates that Man 9 GlcNAc 2 -PP-Dol was converted to Glc 3 Man 9 GlcNAc 2 -PP-Dol by the endogenous DLO biosynthetic pathway.
As the levels of Glc 3 Man 9 GlcNAc 2 -PP-Dol gradually decreased in the organelle fraction, we hypothesized that DLO was catabolized to free Glc 3 Man 9 GlcNAc 2 . To validate this hypothesis, fOSs recovered from the organelle fraction after incubation for the indicated times were labeled and analyzed by size-fractionation HPLC. The results indicated that the free Glc 3 Man 9 GlcNAc 2 oligosaccharide first became detectable at 20 min ( Figure 5B ) and increased in a time-dependent manner.
Glc 3 Man 9 GlcNAc 2 -PP-Dol serves as the optimal donor substrate for the N-glycosylation reaction. To determine if N-glycosylation involving DLO occurred in the organelle fraction of the digitoninpermeabilized Ngly1 −/− Engase −/− MEFs, the N-glycans released from glycopeptides by Endo-H were quantitatively determined (Figure 5C ). However, under the present experimental conditions, DLO was essentially not transferred to proteins. Based on these results and the membrane localization experiments regarding the free Glc 3-Man 9 GlcNAc 2 oligosaccharide ( Figure 5B ), the degradation of Glc 3-Man 9 GlcNAc 2 -PP-Dol appears to result in the formation of the free Glc 3 Man 9 GlcNAc 2 oligosaccharide in the ER lumen of Ngly1
DLO degradation is inhibited in the presence of an N-glycosylation acceptor peptide
To better understand the molecular mechanism responsible for DLO degradation, we examined the involvement of OST (Harada, Buser, et al. 2013) in this process using a synthetic N-glycosylation acceptor peptide (Asn-Tyr-Thr) as an OST substrate. To allow for its efficient delivery to the luminal compartments, where OST catalyzes the N-glycosylation reaction, and to confer resistance against endogenous protease activity, the synthetic peptide was modified with an acetyl group at the N-terminus, and with a blocking amide group at the C-terminus (Welply et al. 1983) . With increasing concentrations of the acetylated acceptor peptide, the formation of free Glc 3 Man 9 GlcNAc 2 was markedly reduced in digitonin-permeabilized Ngly1 −/− Engase −/− MEFs MEFs was incubated for the indicated times, and DLOs (A), fOSs (B) and N-glycans (C) were then analyzed by size-fractionation HPLC (left panels) and quantitated (right panels). The overall pattern of the HPLC charts showed that no remarkable changes had occurred during the incubation periods (data not shown). G3, Glc 3 Man 9 GlcNAc 2 ; G2, Glc 2 Man 9 GlcNAc 2 ; G1, Glc 1 Man 9 GlcNAc 2 ; M9, Man 9 GlcNAc 2 ; G3′, Glc 3 Man 9 GlcNAc 1 ; G2′, Glc 2 Man 9 GlcNAc 1 , and G1′, Glc 1 Man 9 GlcNAc 1 . Error bars indicate SDs from three independent experiments.
( Figure 6A and C) . The IC 50 for the synthetic peptide was estimated to be ∼1 μM, a value that is roughly equivalent to the dissociation constants of mammalian OSTs for the same peptide substrate (Kelleher et al. 2003) . In contrast, a peptide (Gln-Tyr-Thr) that is not recognized as an acceptor by OST had no effect on the formation of free Glc 3-Man 9 GlcNAc 2 oligosaccharide ( Figure 6B and C). These results areconsistent with a previous observation (Spiro and Spiro 1991) showing that the release of fOS is inhibited in the presence of an N-glycosylation acceptor peptide.
Discussion
Mammalian cells generate considerable amounts of fOSs during N-glycosylation reactions (Spiro and Spiro 1991) . Although it has been suggested that fOSs are formed by the deglycosylation of misfolded glycoproteins and the degradation of DLOs (Chantret and Moore 2008) , the contributions of these two distinct pathways to fOS production have not been unambiguously determined in mammalian cells. In the present study, we completely disrupted the pathway for the cytosolic deglycosylation of misfolded glycoproteins in MEFs to assess its role in fOS generation. In the Ngly1 −/− Engase −/− MEFs, the levels of generated fOSs were similar to those for the wild-type MEFs, indicating that the deglycosylation of misfolded glycoproteins does not markedly contribute to the production of fOSs. This finding is in sharp contrast to the case of S. cerevisiae, in which ∼95% of the fOSs were generated in a PNGase-dependent manner (Hirayama et al. 2010; Harada, Buser, et al. 2013) . Furthermore, our data suggest that fOSs are formed and trimmed in the ER lumen and are subsequently transported to the cytosol. Taken together, these findings indicate that the degradation of Glc 3 Man 9 GlcNAc 2 -PP-Dol in the ER lumen is the predominant mechanism for the generation of cytosolic fOSs in mammalian cells. Because the degradation of DLO in the ER lumen is inhibited in the presence of an N-glycosylation acceptor peptide, the catalytic subunit (Stt3 protein) of OST appears to be the most likely candidate enzyme for the hydrolysis of Glc 3 Man 9 GlcNAc 2 -PP-Dol, as was demonstrated in S. cerevisiae (Harada, Buser, et al. 2013) . Similar hydrolytic activity has been reported for Campylobacter jejuni PglB, an ortholog of the catalytic subunit of eukaryotic OST (Nothaft et al. 2009 ). In addition, it has been proposed that the OST-mediated release of fOSs occurs in various types of mammalian cells (Anumula and Spiro 1983; Spiro and Spiro 1991; Gao et al. 2005; Gao and Lehrman 2013) . In the present analyses of Ngly1 −/− Engase −/− double-knockout MEFs, we provide experimental evidence that supports the involvement of OST in DLO degradation. Mammalian cells express two OST catalytic subunits, STT3A and STT3B, which exclusively form OST complexes with multiple accessory proteins (Kelleher et al. 2003) . The two OST complexes are functionally redundant with respect to cotranslational N-glycosylation; however, the STT3B-containing OST complex also catalyzes the posttranslational N-glycosylation of proteins that are fully translated and transported to the ER lumen (Ruiz-Canada et al. 2009 ). The identification of the mammalian OST isoform that plays a central role in DLO degradation would likely provide critical insights into the mechanistic details of the DLO degradation reaction. The amount of cytosolic fOSs generated in Ngly1
MEFs (890 pmol/1 × 10 7 cells) was markedly higher than that (0.10 pmol/1 × 10 7 cells) previously reported in S. cerevisiae mutant cells lacking PNG1 (Chantret et al. 2003; Hirayama et al. 2010; Harada, Buser, et al. 2013) , which indicates that OST-catalyzed degradation appears to be significantly more active in mammalian cells compared with S. cerevisiae. To explain why mammalian OST releases large amounts of fOSs, while yeast OST produces only low levels, it has been proposed that the degradation of DLO in mammalian cells is regulated by mannose 6-phosphate levels and may have a protective function against viral infections by impairing the biosynthesis of glycosylated components of the viral envelope (Gao et al. 2011; Gao and Lehrman 2013) . Clarification of mechanism responsible for the OST-mediated generation of fOSs will be necessary to validate this hypothesis. Our results show that the knockout of Ngly1 has little effect on the level of cytosolic fOSs in MEFs. This finding is consistent with a previous report (Chantret et al. 2010) showing that the knockdown of Ngly1 or the inhibition of Ngly1 activity by a caspase inhibitor results in negligible changes in the amount of fOSs, except for a ∼20% reduction in [2-
3 H]-mannose-labeled Glc 0-1 Man 9 GlcNAc 2 oligosaccharides in HepG2 cells. These observations, together with our current study, indicate that Ngly1 is a minor contributor to the formation of fOSs and that this is likely a general event for mammalian cells. These results are somewhat counterintuitive as it has been estimated that as much as ∼30% of newly synthesized polypeptides are misfolded and degraded by proteasomes in mammalian cells (Schubert et al. 2000) . Since over 50% of the proteins in nature are thought to be glycosylated (Apweiler et al. 1999 ), significant amounts of misfolded glycoproteins are likely generated in mammalian cells, and some of these proteins would be expected to be deglycosylated by Ngly1. These estimations provide information concerning how active the hydrolysis of DLOs can be in mammalian cells. Recently reported findings suggest that subjects with mutations in the NGLY1 gene (NGLY1-deficiency) exist (Need et al. 2012; Enns et al. 2014; Caglayan et al. 2015) . The symptoms include developmental delay, multifocal epilepsy, involuntary movement, abnormal liver function, and the absence of tears. These findings clearly point to the functional importance of Ngly1 in mammals, but the detailed molecular mechanism underlying the pathology of a NGLY1 deficiency is not understood. Based on the current study, however, it appears likely that the formation of fOSs is not a critical factor associated with the pathogenesis of an NGLY1 deficiency.
The present study demonstrates that the ablation of ENGase results in a reduction in the levels of Man 5 GlcNAc 1 , as well as the accumulation of Gn2-type fOSs in the cytosol of MEFs. These findings are consistent with the phenotype resulting from an ENGase mutation in Caenorhabditis elegans (Kato et al. 2007 ) and unambiguously demonstrate that ENGase is required for the Gn2-to-Gn1 conversion of cytosolic fOSs. In MEFs lacking ENGase, a large fraction of the accumulated cytosolic fOSs was found to be composed of Man [8] [9] GlcNAc 2 , clearly indicating that the Man2C1-catalyzed removal of mannose residues was impaired. This observation is consistent with the fact that Man2C1 shows higher substrate specificity for Gn1 type fOSs over the Gn2 type in vitro (Oku and Hase 1991; Kumano et al. 1996; Yamashiro et al. 1997) . The findings presented herein further confirm that the action of ENGase is prerequisite for the efficient trimming of mannose residues in mammalian cells.
In conclusion, we report that the degradation of DLO leads to the production of a large fraction of the cytosolic fOSs in mammalian cells, and that this process may involve the hydrolytic activity of OST. In S. cerevisiae, however, fOSs are almost exclusively produced by the deglycosylation of misfolded glycoproteins. The identification of factors that contribute to determine the contribution of the two distinct pathways will provide deeper insights into the regulatory mechanism of N-glycosylation, as well as DLO metabolism.
Experimental procedures
Preparation and cultivation of MEFs
MEFs from wild-type, Ngly1 −/− , Engase −/− and Ngly1 −/− Engase −/− double-knockout mice were prepared and immortalized as described previously (Huang et al. 2015) . The prepared MEFs (1 × 10 6 cells)
were seeded in a 10 cm dish and cultivated in Dulbeccos' Modified Eagle's Medium (DMEM), supplemented with 25 mM glucose, 10% (vol/vol) fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin, at 37°C for 48 h in a 5% CO 2 atmosphere.
Castanospermine and kifunensine treatment of MEFs
Ngly1 −/− Engase −/− MEFs (1 × 10 6 cells) were cultivated in a 10 cm dish in DMEM for 48 h. KIF was then added to the culture medium at a concentration of 0.1 mM, and the cells were further incubated for 1 h at 37°C. CST was then added directly to the culture medium of the KIF-treated cells at a concentration of 1 mM, and the cells were further incubated for 8 h at 37°C.
Preparation of fOSs, DLOs and N-glycans from MEFs
fOSs and DLOs were prepared from MEFs as described previously (Harada, Nakajima, et al. 2013) . To prepare N-glycans, a delipidated cell pellet obtained from 1.5 × 10 7 cells was digested with a 1 mg/mL solution of trypsin in 500 μL of 10 mM ammonium bicarbonate for 3 h at 37°C. A 500 μL fresh trypsin solution was added to the sample, which was further incubated for 16 h at 37°C. After inactivation of trypsin by heating at 100°C for 10 min, N-glycans were released by treatment of the sample with 10 mU Endo-H (Roche) for 16 h at 37°C. The released glycans were desalted on a column containing a stack of AG50-X8 (250 μL, 200-400 mesh, H + form; Bio-Rad) and AG1-X2 resins (250 μL, 200-400 mesh, acetate form; Bio-Rad), followed by an InertSep GC column (graphitized carbon column; 150 mg/3 mL; GL Sciences) (Hirayama et al. 2010) .
Pyridylamination
Fluorescent labeling of purified glycans with 2-aminopyridine (PA) was performed as described previously (Hirayama et al. 2010 ).
Size-fractionation HPLC
PA-labeled glycans were separated by size-fractionation HPLC with an NH2P-50 4E column (4.6 × 250 mm; Shodex), as described previously (Harada, Buser, et al. 2013 ).
Dual-gradient, reversed-phase HPLC analysis
To deduce the isomeric structures of the PA-labeled glycans, dualgradient, reversed-phase HPLC analysis using an Inertsil ODS-3 column (2.1-mm inner diameter × 150 mm; GL Sciences) was performed, as described previously (Suzuki et al. 2008) . PA-labeled glycans were quantitated based on the fluorescent intensity of isomaltohexaose in a standard PA-labeled glucose oligomer (degree of polymerization = 3-15; Takara).
Digitonin permeabilization
Ngly1 −/− Engase −/− MEFs (6 × 10 7 cells) were harvested by trypsinization and washed twice with 25 mL ice-cold phosphate-buffered saline (PBS). The washed cells were resuspended in 1 mL PBS, added to 1 mL PBS supplemented with 0-0.06% (wt/vol) digitonin and then incubated for 5 min at 0°C. The digitonin-permeabilized cells were centrifuged at 1000 × g for 5 min, and the resulting supernatant was recovered as the cytosolic fraction (2 mL). The remaining organelle fraction was washed once with 4 mL of PBS and again centrifuged at 1000 × g for 5 min. The supernatant was combined with the cytosolic fraction (6 mL total) and the organelle fraction was resuspended in 6 mL PBS. fOSs were extracted from the cytosolic and organelle fractions by the addition of 18 mL ethanol, followed by incubation for 15 min at 0°C. After centrifugation at 15,000 × g for 15 min, the supernatant was dried and desalted using an InertSep GC column (150 mg/3 mL). The obtained eluate was evaporated to dryness and desalted on a column containing a stack of AG50-X8 (250 μL, 200-400 mesh, H + form) and AG1-X2 resins (250 μL, 200-400 mesh, acetate form). To perform the fOS-releasing assay, the organelle fraction was washed twice with 10 mL of a buffer containing 20 mM HEPES-KOH ( pH 7.4), 150 mM KCl, 5 mM MgCl 2 , 5 mM MnCl 2 and 5 mM CaCl 2 , and was then resuspended in the same buffer at a concentration corresponding to 6.0 × 10 7 cells/mL.
Solubilization of the organelle fraction
Triton X-100 was added at a concentration of 1% (wt/vol) to the organelle fraction obtained from digitonin-permeabilized Ngly1 −/− Engase −/− MEFs, and the resulting sample was incubated for 15 min at 0°C. The homogenate was centrifuged at 15,000 × g for 5 min and the supernatant was recovered as a solubilized organelle fraction.
LDH activity assay
LDH activity in the cytosolic and solubilized organelle fractions from the digitonin-permeabilized Ngly1 −/− Engase −/− MEFs was measured using a cytotoxicity detection kit (LDH; Roche) according to the manufacturer's instruction.
β-HexNAcase activity assay β-HexNAcase activity in the cytosolic and solubilized organelle fractions from digitonin-permeabilized Ngly1 −/− Engase −/− MEFs was measured using p-nitrophenyl β-GlcNAc as the substrate, as described previously (Harada, Nakajima, et al. 2013 ).
Western blotting
The cytosolic and solubilized organelle fractions from the digitoninpermeabilized Ngly1 −/− Engase −/− MEFs (1.0 × 10 5 cells) were separated by SDS-PAGE and then electroblotted onto a polyvinylidene fluoride membrane. The membrane was blocked for 1 h with 5% (wt/vol) skim milk in PBS supplemented with 0.05% (wt/vol) Tween20 (PBST) and then incubated for 1 h with rabbit anti-PDI antibody (1 : 1000; Cell Signaling Technology). The membrane was washed three times with PBST, followed by a 45 min incubation with horseradish peroxidase-conjugated anti-rabbit IgG antibody (1 : 5000; Cell Signaling Technology). The membrane was again washed three times with PBST and then incubated with Immobilon Western Chemiluminescent HRP Substrate (Millipore). Chemiluminescence was immediately visualized using a LAS-3000 Imager (Fujifilm). Western blotting using mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1 : 10,000 dilution; Millipore) was also conducted in a similar manner with HRP-conjugated anti-mouse IgG (1 : 5000 dilution) as secondary antibody.
fOS-releasing assay
The organelle fraction from the digitonin-permeabilized Ngly1 −/− Engase −/− MEFs (250 μL, 1.5 × 10 7 cells) was preincubated with
